Satellos Bioscience Inc.
TSX:MSCL.TO · Toronto Stock Exchange
+$0.01 today
Vol 0.00M · Avg 0.02M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
TSX:MSCL.TO · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$27.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.80, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $5.1K -74.6% | $20.0K -99.8% | $8.8M +136.1% | $3.7M +2153.7% | $165.7K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$5.1K +74.6% | -$20.0K +99.8% | -$8.8M -136.1% | -$3.7M -2153.7% | -$165.7K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $18.7M -4.4% | $19.6M +122.3% | $8.8M +240.9% | $2.6M +37.3% | $1.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $7.4M -9.1% | $8.2M +23.3% | $6.6M +21.0% | $5.5M +95.7% | $2.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $26.9M -3.1% | $27.8M +79.7% | $15.5M +229.4% | $4.7M -0.2% | $4.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $5.1K -74.6% | $20.0K +185.7% | $7.0K -97.9% | $337.0K +103.4% | $165.7K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$26.9M +4.1% | -$28.1M -78.8% | -$15.7M -94.1% | -$8.1M -75.8% | -$4.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$26.9M +3.2% | -$27.8M -79.8% | -$15.5M -83.5% | -$8.4M -26.8% | -$6.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.4M +0.9% | $1.4M +2.9% | $1.3M +2015.9% | $63.0K +688.9% | $8.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 -100.0% | $177.0K | $0 -100.0% | $985.3K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.8M +714.7% | -$291.0K +31.7% | -$426.0K +85.3% | -$2.9M +67.4% | -$8.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$25.1M +10.6% | -$28.1M -76.8% | -$15.9M -40.4% | -$11.3M +27.0% | -$15.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $175.0K | $0 | $0 -100.0% | $5.0K +111.8% | -$42.4K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$25.3M +9.9% | -$28.1M -76.8% | -$15.9M -40.3% | -$11.3M +27.0% | -$15.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +41.2% | -$3 -33.0% | -$2 +42.0% | -$4 +50.7% | -$8 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +41.2% | -$3 -33.0% | -$2 +42.0% | -$4 +50.7% | -$8 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $14.6M +52.6% | $9.6M +32.8% | $7.2M +142.2% | $3.0M +48.2% | $2.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $14.6M +52.6% | $9.6M +32.8% | $7.2M +142.2% | $3.0M +48.2% | $2.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Quipt Home Medical Corp.
QIPT.TO
$221.44M
Cannara Biotech Inc.
LOVE.V
$181.03M
Cardiol Therapeutics Inc.
TSX:CRDL.TO
$171.76M
BioSyent Inc.
RX.V
$160.02M
Cybin Inc.
CYBN.NE
$157.10M
Grown Rogue International Inc.
GRIN.CN
$149.96M
Helix BioPharma Corp.
TSX:HBP.TO
$108.46M
Zentek Ltd.
ZEN.V
$62.38M
Sernova Corp.
TSX:SVA.TO
$53.90M
Medicenna Therapeutics Corp.
MDNA.TO
$28.87M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MSCL.TO generate?
Satellos Bioscience Inc. (MSCL.TO) reported $0.00 of revenue in fiscal 2025.
Is MSCL.TO profitable?
Satellos Bioscience Inc. (MSCL.TO) reported -$25,308,414.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.